Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deferred Tax Liability: 2019-2025

Historic Non-Current Deferred Tax Liability for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $2.4 million.

  • Revolution Medicines' Non-Current Deferred Tax Liability fell 24.46% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 24.46%. This contributed to the annual value of $2.4 million for FY2024, which is 24.46% down from last year.
  • Latest data reveals that Revolution Medicines reported Non-Current Deferred Tax Liability of $2.4 million as of Q3 2025, which was down 0.00% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non-Current Deferred Tax Liability registered a high of $7.4 million during Q1 2021, and its lowest value of $2.4 million during Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $3.1 million (2024), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Revolution Medicines' Non-Current Deferred Tax Liability climbed by 5.07% in 2021, and later tumbled by 55.82% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.4 million in 2021, then fell by 5.63% to $7.0 million in 2022, then tumbled by 55.66% to $3.1 million in 2023, then dropped by 24.46% to $2.4 million in 2024, then decreased by 24.46% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.4 million for Q2 2025, and $2.4 million during Q1 2025.